Tick-borne Encephalitis and Possible Borrelial Serology
NCT03958058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 690
Last updated 2019-05-21
Summary
In Europe, tick-borne encephalitis (TBE) virus causing TBE is transmitted by the bite of Ixodes ricinus tick, which can also transmit Lyme borreliae , the causative agent of Lyme borreliosis (LB). Since TBE and LB are both endemic with high incidence rates in Slovenia, we should be attentive to the possibility of double infections. Double infections with TBE virus and Lyme borreliae were reported to occur rarely even in endemic countries, however reliable data on coinfection rates are rather limited. Microbiological diagnosis of TBE virus infection is quite straightforward, and there is no specific therapy for TBE available so far. This markedly differs from borrelial infection, in which case interpretation of serological test results demands more caution, but there is highly efficient antibiotic treatment available for LB. This may lead to over prescribing of antibiotics to TBE patients with documented borrelial antibodies in serum indicating possible coinfection with Lyme borreliae, but missing clinical or microbiological criteria for proven borrelial coinfection. Approximately 10% of patients who had been treated appropriately for LB and about one third of patients after TBE report nonspecific subjective complaints, such as fatigue, headache, arthralgia, and myalgia, termed post-Lyme and post-encephalitic symptoms, respectively. These may not be differentiated clearly from nonspecific symptoms occurring with a rather substantial incidence also in the general population. A trend of ascribing medically unexplained nonspecific subjective symptoms to LB in subjects with positive borrelial antibodies in serum puzzles the situation further.
The aim of this prospective observational study was to assess the proportion and clinical implication of proven and possible coinfection with Lyme borreliae in patients with TBE, and to evaluate the association between anti-borrelial antibiotic therapy and clinical outcome in the subgroup of patients with possible coinfection.
Conditions
- Tick Borne Encephalitis
- Lyme Disease
Interventions
- DRUG
-
Anti-borrelial antibiotic therapy
Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
- OTHER
-
No antibiotic.
Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Sponsors & Collaborators
-
University of Ljubljana School of Medicine, Slovenia
collaborator OTHER -
University Medical Centre Ljubljana
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-01
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
Countries
- Slovenia
Study Locations
More Related Trials
-
Tick-borne Encephalitis Virus Research in Limousin
NCT05941546 ·Status: COMPLETED
-
Clinical Manifestations and Long-Term Outcome in Early Lyme Neuroborreliosis
NCT04653558 ·Status: COMPLETED
-
Inflammatory Responses in Solitary and Multiple Erythema Migrans
NCT03980015 ·Status: COMPLETED
-
Evolving Diagnostic Approaches to Undocumented Lymphocytic Meningitis and Meningoencephalitis
NCT07186881 ·Status: ENROLLING_BY_INVITATION
-
Erythema Migrans in Elderly
NCT03371563 ·Status: COMPLETED
-
Study on Early Lyme Neuroborreliosis
NCT00910533 ·Status: UNKNOWN ·Phase: NA
-
Anti-phospolipid Antibodies in Lyme Borreliosis
NCT06929546 ·Status: NOT_YET_RECRUITING
-
Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu Lato
NCT06835075 ·Status: ACTIVE_NOT_RECRUITING
-
Searching for Persistence of Infection in Lyme Disease
NCT01143558 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis
NCT00942006 ·Status: UNKNOWN ·Phase: NA
-
Direct Diagnosis of Disseminated Lyme Borreliosis.
NCT04719962 ·Status: UNKNOWN ·Phase: NA
-
Doxycycline in Therapy of Erythema Migrans
NCT01475708 ·Status: COMPLETED
-
Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia
NCT07335965 ·Status: RECRUITING
-
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
NCT00001539 ·Status: RECRUITING
-
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
NCT00028080 ·Status: RECRUITING
-
Characteristics of Lyme Arthritis
NCT03510507 ·Status: UNKNOWN
-
Inflammatory Mediators in Erythema Migrans
NCT03956212 ·Status: COMPLETED ·Phase: NA
-
Understanding Tick-borne Diseases
NCT03501407 ·Status: UNKNOWN
-
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
NCT03010228 ·Status: COMPLETED ·Phase: PHASE1
-
Risk of Exposure and Prevention of Ticks and Tick-borne Diseases Among Foresters in Alsace
NCT06492668 ·Status: RECRUITING
-
Patient's Pretreatment Expectations About Post-Lyme Symptoms
NCT03462329 ·Status: RECRUITING ·Phase: NA
-
A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
NCT07226882 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluation and Follow-up of People With Tick-borne Diseases
NCT04318925 ·Status: WITHDRAWN
-
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
NCT00138801 ·Status: COMPLETED ·Phase: PHASE3
-
Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis
NCT05625100 ·Status: UNKNOWN